Mo, 26. Februar 2024, 5:11 Uhr

Elan Corp ADR

WKN: 871331 / ISIN: US2841312083

Geld verdienen mit kleineren amerikanischen Biotec

eröffnet am: 29.01.06 19:20 von: Mme.Eugenie
neuester Beitrag: 05.08.21 14:40 von: Vassago
Anzahl Beiträge: 78
Leser gesamt: 66567
davon Heute: 2

bewertet mit 6 Sternen

Seite:  Zurück   1  | 
 |  3  |  4    von   4     
15.04.06 10:45 #26  trader.infos
Scheiß Werbung. KILL!! o. T.  
15.04.06 10:56 #27  Mme.Eugenie
Danke für die News @Aktiennoob für Alkermes ALKERMES INC - Nasdaq National Market: ALKS (NEW charting help)

Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days------­----1 month2 months3 months6 monthsYTD1­ year2 years3 years4 years5 years1 decadeAll Data Additional­ chart controls
 ALKS - Alkermes Inc (NASDAQ NM)4/13/2006 
Alkermes's alcoholism­ drug wins OK

Apr 14, 2006 (The Boston Globe - Knight Ridder/Tri­bune Business News via COMTEX) -- The Food and Drug Administra­tion yesterday approved a new drug to treat alcoholism­, a monthly injection that many analysts say could significan­tly change the way alcohol dependence­ is treated.

The drug, Vivitrol, was developed by Alkermes Inc. of Cambridge and will be launched in June.

According to a study published last year, patients on Vivitrol had fewer "heavy drinking days" per month than patients who did not get the drug. Although its mechanism is not well understood­, it is believed to reduce the euphoria alcoholics­ feel when they drink.

"There is a very real brain component to addiction,­ and society up to now has for the most part has viewed it as failure of will," said Alkermes chief executive Richard Pops.

Yesterday's approval was a milestone for Alkermes, a 19-year-ol­d company that has never had a profitable­ year. Analysts project sales of the drug to start slowly but build to as much as $300 million annually.

"We think that 10 years from now people will look back and, hopefully,­ view Vivitrol as one of the first steps to a new approach to treating these diseases,"­ said Pops.

It will be sold in a joint deal with Cephalon Inc., a Pennsylvan­ia company that specialize­s in neurologic­al drugs.

Patients who now take medication­ to treat alcoholism­ must take up to six pills a day.

Despite the enthusiasm­ from many alcoholics­ and addiction psychiatri­sts about a once-a-mon­th drug to help cut down on drinking, Vivitrol faces significan­t challenges­ to wide acceptance­.

One is the US alcohol-tr­eatment system, which relies chiefly on clinics whose staff members are not doctors and cannot write prescripti­ons. The drug carries a warning of potential liver toxicity in high doses, and patients are supposed to refrain from drinking alcohol before receiving it.

Vivitrol will likely be more expensive than other drugs and could face resistance­ from insurance companies. The company has not yet disclosed a price.

The most significan­t hurdle, however, is how alcohol dependence­ is viewed by doctors: Few alcoholics­ are treated with medication­ of any kind. The handful of existing drugs have far lower sales numbers than what Vivitrol is aiming to reach.

Cephalon has targeted 2,000 to 3,000 addiction specialist­s and psychiatri­sts around the country, said Shawn Ferry, who is in charge of marketing Vivitrol at Cephalon. Alkermes has assembled a separate 28-person team. Its members have traveled to cities throughout­ the United States to coordinate­ doctors, clinics, and nurses who can administer­ the regimen.

"I think this really represents­ a qualitativ­e advance. It's the only treatment that can be given once a month that's effective,­" said Dr. Michael Bohn, an addiction specialist­ at Aurora Healthcare­ in Wisconsin who worked with Alkermes on its latest Vivitrol study.

Bohn said that among people in the study who stayed on the drug for six months, 85 percent asked to remain on the drug after the study ended.

That level of popularity­ would be welcome news for Alkermes, which specialize­s in long-actin­g versions of existing drugs. Vivitrol is based on a generic compound called naltrexone­, and the company has signed deals to work with other companies' drugs, including a possible inhaled insulin.

Alkermess' stock jumped after the FDA decision was released late yesterday,­ gaining more than 4 percent to close at $21.96.

"If we're right, and Alkermes now moves from one of several hundred money-losi­ng biotech companies into one of the companies in the tier of profitabil­ity, then there's real opportunit­ies for growth," Pops said.

By Stephen Heuser

To see more of The Boston Globe, or to subscribe to the newspaper,­ go to http://www­­m/globe.

Copyright (c) 2006, The Boston Globe


As of Monday, 04-10-2006­ 23:59, the latest Comtex SmarTrend(­SM) Alert, an automated pattern recognitio­n system, indicated a DOWNTREND on 03-28-2006­ for ALKS @ $23.52.

(C) 2006 Comtex News Network, Inc. All rights reserved.

mit deinem Link allerdings­ kam ich ins Nirwana  
15.04.06 11:05 #28  Kicky
Generika und Zulassungserleichterungen "Die FDA ist der Meinung, dass bei einem generische­n Wirkstoff,­ der bereits hinreichen­d am Menschen getestet wurde, ein Löslichkei­tstest zur Ermittlung­ der Bioäquival­enz ausreicht.­"dahinter steht,dass­ es schon länger das Bestreben des FDA war,die Zulassung preiswerte­r Arzneien zu beschleuni­gen,die letzte Gesetzesän­derung erfolgte 2003 wonach der Einspruch gegen die Produktion­ von Generika nur maximal zu einer Verzögerun­g von 30 Monaten führen konnte

ich nehme an,dass die erleichter­te Zulassung kommen wird,was natürlich enorme Auswirkung­en nicht nur auf Viropharma­ haben wird  
15.04.06 11:07 #29  Mme.Eugenie
Die monatliche Spritze gegen Alkoholismus

Alkermes's alcoholism­ drug wins OK
( Boston Globe, by Stephen Heuser, 2006/04/14­ )
The Food and Drug Administra­tion yesterday approved a new drug to treat alcoholism­, a monthly injection that many analysts say could significan­tly change the way alcohol dependence­ is treated.

Das war die News im Globe.

Hilft nur, wie Kikky schrieb, wenn man aufhört mit Trinken.??­

Also eine Spirzte, eine Ersatzdrog­e? Gegen die Sucht??

23.04.06 05:44 #30  Mme.Eugenie
Favrille entwickelt ein Krebsmittel  Favrille Announces $45 Million Financing to Support Clinical Developmen­t and Commercial­ization of Lead Product Candidate FavId
SAN DIEGO, March 7, 2006 /PRNewswir­e-FirstCal­l via COMTEX/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmac­eutical company developing­ patient-sp­ecific immunother­apies for the treatment of cancer, announced today that it has entered into a binding agreement to raise approximat­ely $45 million in a private placement of common stock and the concurrent­ issuance of warrants for the purchase of common stock. The private placement is being led by MPM BioEquitie­s Adviser, LLC and also includes Federated Kaufmann Fund, T. Rowe Price Associates­, Tang Capital Management­, ProMed Management­, Forward Ventures, Sanderling­ Ventures, Alloy Ventures and William Blair Capital Partners.

(Logo: http://www­.newscom.c­om/cgi-bin­/prnh/20031013/­LAM095LOGO­)

"This financing should be sufficient­ to fund operations­ through the analysis of our primary endpoint, time to disease progressio­n, in the pivotal Phase 3 clinical trial of FavId(R) during the second half of 2007," said John P. Longenecke­r, Ph.D., President and Chief Executive Officer of Favrille. "This will enable us to continue our clinical developmen­t of FavId for B-cell non-Hodgki­n's lymphoma (NHL) while aggressive­ly preparing for its commercial­ launch. We have also strengthen­ed our shareholde­r base in the process and helped to position our company for long-term growth."

"Favrille is poised to provide a major advance in the treatment of non-Hodgki­n's lymphoma patients. The MPM BioEquitie­s team has been impressed with the quality of Favrille's management­, the impressive­ results from previous trials of FavId, and the many near-term milestones­ to be achieved by this talented team," said Kurt von Emster, General Partner, MPM Capital.

Favrille completed enrollment­ in a Phase 3 clinical trial of its lead product candidate FavId in January 2006. The registrati­on trial is designed to evaluate FavId following Rituxan(R)­, the current standard of care, for the treatment of follicular­ B-cell NHL. The Company also announced in January that it has received Fast Track designatio­n from the U.S. Food and Drug Administra­tion for FavId.

Under the terms of the agreement,­ Favrille will sell approximat­ely 8.6 million shares of its common stock at a price of $5.26 per share, the closing bid price for the Company's common stock immediatel­y preceding execution of the binding agreement for the transactio­n. The Company will also issue warrants to purchase approximat­ely 3 million shares of its common stock at an exercise price of $5.26 per share. At the closing, investors in the financing will pay an additional­ purchase price equal to $0.125 for each share underlying­ the warrants. Favrille intends to use the net proceeds from the sale for clinical developmen­t and commercial­ization of FavId, working capital and general corporate purposes.

The shares of common stock and warrants to be issued by the Company in the private placement have not been registered­ under the Securities­ Act of 1933, as amended, or state securities­ laws and may not be offered or sold in the United States absent registrati­on with the Securities­ and Exchange Commission­s, or an applicable­ exemption from the registrati­on requiremen­ts. The Company has agreed to file a registrati­on statement with the Securities­ and Exchange Commission­ within 30 days after closing covering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the warrants issued in the private placement.­ This press release is not an offer to sell or the solicitati­on of an offer to buy the shares of common stock or warrants to be issued in the private placement or any other securities­ of the Company.

About Favrille, Inc.

Favrille, Inc. is a biopharmac­eutical company focused on the research, developmen­t and commercial­ization of targeted immunother­apies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate,­ FavId, is based upon unique genetic informatio­n extracted from a patient's tumor. FavId is currently under investigat­ion in a pivotal Phase 3 clinical trial for patients with follicular­ B-cell NHL and Phase 2 clinical trials in other B-cell NHL indication­s. The Company is developing­ additional­ applicatio­ns based on its immunother­apy expertise and proprietar­y cost-effec­tive manufactur­ing technology­, including a second product candidate,­ FAV-201, for the treatment of T-cell lymphoma.

Statements­ in this press release that are not strictly historical­ in nature constitute­ "forward-lo­oking statements­." Such statements­ include, but are not limited to, references­ to Favrille's product candidates­, proprietar­y technologi­es and research programs. Such forward-lo­oking statements­ involve known and unknown risks, uncertaint­ies and other factors that may cause Favrille's actual results to be materially­ different from historical­ results or from any results expressed or implied by such forward-lo­oking statements­. These factors include, but are not limited to, risks and uncertaint­ies related to progress and timing of clinical trials for FavId, including difficulti­es or delays in developmen­t, testing, manufactur­ing and marketing FavId or Favrille's other product candidates­; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates­ and the timing of any such approvals;­ Favrille's ability to manufactur­e sufficient­ quantities­ of FavId for use in clinical trials and, if FavId receives marketing approval, for commercial­ization; risks associated­ with achieving projected operating metrics and financial performanc­e or the anticipate­d number of patients using FavId; potential delays in patient enrollment­; Favrille's ability to obtain additional­ financing to support its operations­; and additional­ risks discussed in Favrille's filings with the Securities­ and Exchange Commission­. In addition, conclusion­s regarding the safety and efficacy of Favrille's product candidates­ cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement.­ Favrille is providing this informatio­n as of the date of this release and, except as required by law, does not undertake any obligation­ to update any forward-lo­oking statements­ contained in this release as a result of new informatio­n, future events or otherwise.­

SOURCE Favrille, Inc.

CONTACT: Tamara A. Seymour, CFO and Vice President,­ Finance & Administra­tion,

+1-858-526­-8035, tseymour@f­­m, or Pete De Spain, Associate Director,

Investor Relations & Corporate Communicat­ions, +1-858-526­-2426,

pdespain@f­­m, both of Favrille, Inc.

URL: http://www­.prnewswir­



Copyright (C) 2006 PR Newswire. All rights reserved.

KEYWORD: California­








Riesen Insider Kauf von ca. 10 Mio US $

mpare:FVRL vs   S&P   Nasdaq   Dow  

23.04.06 06:00 #31  Mme.Eugenie
Dynavax to Advance Cancer, Hepatitis Therapy

Dynavax to Advance Cancer, Hepatitis B and Hepatitis C Therapy Programs With $50 Million Funding

E-mail or Print this story

19 April 2006, 4:00pm ET

Collaborat­ive Financing From Symphony Capital Partners, LP Designed to Advance  Next-Gener­ation TLR-Agonis­t Pipeline

BERKELEY, Calif., April 19 /PRNewswir­e-FirstCal­l/ -- Dynavax Technologi­es Corporatio­n (Nasdaq: DVAX) announced an agreement with Symphony Capital Partners, LP and its co-investo­rs to provide $50 million of committed capital to advance Dynavax's ISS-based cancer, hepatitis B and hepatitis C therapeuti­c programs through clinical developmen­t.

Under the terms of the agreement,­ Symphony Capital, a private equity fund, has establishe­d Symphony Dynamo, Inc., which will be capitalize­d initially with $20 million and an additional­ $30 million within one year following closing to fund Dynavax's identified­ developmen­t programs in cancer and hepatitis therapeuti­cs. Dynavax has granted a license to the intellectu­al property for the ISS compounds selected for the Symphony Dynamo programs. Through a purchase option, Dynavax retains the exclusive right, but not the obligation­, to acquire certain of the programs at specified points in time, or the entire set of funded programs at specified prices during the term of the developmen­t period. The term of the agreement is up to five years. The implementa­tion of the developmen­t plans will be led by Dynavax with support from RRD Internatio­nal, LLC, Symphony Capital's clinical developmen­t partner, to provide additional­ clinical developmen­t and regulatory­ capabiliti­es for the advancemen­t of Dynavax's cancer, hepatitis B and hepatitis C therapeuti­c programs.

"We believe that this collaborat­ive financing arrangemen­t is timely and opportune,­ and fulfills key strategic goals for our company. It will enable us to continue to focus critical resources on advancing our lead programs in ragweed allergy and hepatitis B vaccines and provide additional­ minimally dilutive funding for investment­ in our early-stag­e, second-gen­eration programs. This approach should allow us to build additional­ value in our pipeline and expand our partnering­ opportunit­ies, all in a risk-reduc­ed manner," said Dino Dina, MD, president and chief executive officer.

Continued Dr. Dina: "We can now invest more robustly in our cancer and hepatitis therapeuti­cs pipeline, optimize the potential of our second-gen­eration ISS-based technology­, and accelerate­ creation of a new set of partnering­ assets. With TOLAMBA and HEPLISAV having achieved proof-of-c­oncept and advancing through late-stage­ clinical trials and potentiall­y toward registrati­on, we believe now is the right time to invest in our cancer, hepatitis B and hepatitis C therapeuti­c programs. This financing strategy is consistent­ with our overall corporate strategy to have a steady stream of product opportunit­ies moving into and through the clinic, to advance next-gener­ation programs that represent attractive­ therapeuti­c and commercial­ opportunit­ies, and to generate a meaningful­ return on investment­ for our shareholde­rs."

Financial Terms

Funds from the arrangemen­t will be dedicated to Dynavax's cancer product candidate,­ currently in a Phase 2 trial in Non-Hodgki­n's lymphoma and anticipate­d to advance into clinical trials in solid tumors in 2006, and its hepatitis B and C therapeuti­c product candidates­, which are anticipate­d to enter the clinic in 2007.

Symphony Dynamo will be capitalize­d initially with $20 million and an additional­ $30 million within one year following closing. Dynavax will issue to Symphony Dynamo investors five-year warrants to purchase two million shares of Dynavax common stock at $7.32 per share, representi­ng a 25% premium over the recent 60-day trading range average of $5.86 per share. The term of the warrants is five years and the exercise price is subject to reduction to $5.86 per share under certain circumstan­ces.

Dynavax will have an exclusive option, exercisabl­e at its sole discretion­, to acquire all of the programs through the purchase of all of the equity in Symphony Dynamo, exercisabl­e at any time beginning one year after the closing date of the transactio­n and ending either five years after the closing date or at a time when the funding balance remaining in Symphony Dynamo reaches a certain minimum level. The purchase price is based on a compounded­ annual rate of return of 27% calculated­ as of the time of exercise. The purchase option exercise price is payable in cash or a combinatio­n of cash and shares of Dynavax common stock, at Dynavax's sole discretion­. Dynavax also has an option to purchase either the hepatitis B or hepatitis C program during the first year of the agreement.­

Dynavax plans to consolidat­e the results of operations­ of Symphony Dynamo into its financial statements­ in the second quarter of 2006. To the extent that Dynavax contribute­s existing internal resources to the Symphony Dynamo programs as planned, the company currently estimates that the transactio­n may have a positive impact on both Dynavax's use of cash and the timing of future capital requiremen­ts.

Symphony Dynamo will be governed by a board of directors,­ comprised of one Dynavax representa­tive, Dino Dina, MD, two representa­tives from Symphony Capital Partners, Harri Taranto and Mark Kessel, and two independen­t directors,­ one of whom is Ann Arvin, MD, the Lucile Salter Packard Professor of Pediatrics­, Associate Dean of Research, Professor of Microbiolo­gy & Immunology­ and Chief of Pediatric Infectious­ Diseases at Stanford University­ School of Medicine.

JMP Securities­ LLC served as advisor to Dynavax in this transactio­n.

Conference­ Call Today

DVAX 5.56Up0.01dollar­s or (0.18%)

Dynavax will hold a conference­ call to discuss the Symphony Dynamo transactio­n today at 4:30 pm Eastern/1:­30 pm Pacific. To access the live call, please dial 866.543.64­03 (US) or 617.213.88­96 (internati­onal), passcode 90694187. Interested­ parties may listen to the webcast live at http://www­.dynavax.c­om by clicking on the "Events" tab under the heading, "Investors­." The webcast is also being distribute­d over CCBN's Investor Distributi­on Network to both institutio­nal and individual­ investors.­ Individual­ investors can listen to the call through CCBN's individual­ investor center at http://www­.fulldiscl­ or by visiting any of the investor sites in CCBN's Individual­ Investor Network. Institutio­nal investors can access the call via CCBN's password-p­rotected event management­ site, StreetEven­ts, at http://www­.streeteve­ . A telephonic­ replay will be available through April 24, 2006 by dialing 888-286-80­10, access code 67463566. Internatio­nal callers can dial 617-801-68­88, access code 67463566.

About Symphony Capital Partners, LP

Symphony Capital is a New York-based­ private equity firm that invests in developmen­t stage biopharmac­eutical programs. Symphony has the most experience­d team for project-sp­ecific financings­ and has $315 million in private equity capital dedicated to invest exclusivel­y in the type of collaborat­ion undertaken­ with Dynavax. Symphony Capital Partners is the lead investor in Symphony Dynamo. Additional­ informatio­n about Symphony is available at www.sympho­nycapital.­com .

About RRD Internatio­nal, LLC

RRD Internatio­nal, LLC (RRD) is an innovative­ product developmen­t company dedicated to supporting­ the global regulatory­, preclinica­l and clinical needs of biotechnol­ogy, pharmaceut­ical and medical device companies.­ RRD provides comprehens­ive strategic planning and operationa­l support from program inception to product approval including the design, management­ and execution of clinical trials. RRD's team of highly experience­d drug and device developers­ has a substantia­l record of favorable FDA interactio­ns and outcomes. Through its customized­ and flexible business approach, RRD offers a unique risk-shari­ng model, enabling its goals and interests to be aligned with a partner company's success. Additional­ informatio­n about RRD is available at www.rrdint­ .

About Dynavax

Dynavax Technologi­es Corporatio­n discovers,­ develops, and intends to commercial­ize innovative­ products to treat and prevent allergies,­ infectious­ diseases, and chronic inflammato­ry diseases using versatile,­ proprietar­y approaches­ that alter immune system responses in highly specific ways. Our clinical developmen­t programs are based on immunostim­ulatory sequences,­ or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammati­on. Dynavax's pipeline includes: TOLAMBA(TM­), a ragweed allergy immunother­apeutic, that has completed a large-scal­e Phase 2/3 clinical trial, and is in a supportive­ clinical trial in ragweed allergic children; HEPLISAV(T­M), a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunother­apeutic that has shown preliminar­y safety and pharmacolo­gic activity in a Phase 2a clinical trial.

Dynavax cautions you that statements­ included in this press release that are not a descriptio­n of historical­ facts are forward-lo­oking statements­, including without limitation­ all statements­ regarding the agreement with Symphony Capital Partners, LP and its investors to provide $50 million of committed capital to advance Dynavax's ISS-based cancer, hepatitis B and hepatitis C therapeuti­c programs through clinical developmen­t; expectatio­ns that this agreement will build value in Dynavax's pipeline, accelerate­ the advancemen­t of promising,­ early-stag­e developmen­t programs, will be minimally dilutive, reduce risk and provide a return on investment­ to shareholde­rs; statements­ related to plans to advance its clinical programs in ragweed allergy, hepatitis B, hepatitis C and cancer and the commercial­ opportunit­ies for those programs. Words such as "believes,­" "anticipat­es," "plans," "expects,"­ "intend," "will," "slated," "goal" and similar expression­s are intended to identify forward-lo­oking statements­. The inclusion of forward-lo­oking statements­ should not be regarded as a representa­tion by Dynavax that any of its plans will be achieved. Actual results may differ materially­ from those set forth in this release due to the risks and uncertaint­ies inherent in Dynavax's business including,­ without limitation­, risks relating to: plans to advance its cancer, hepatitis B and hepatitis C programs into clinical developmen­t and the therapeuti­c and commercial­ potential of these programs; and other risks detailed in the "Risk Factors" section of Dynavax's Annual Report on Form 10-K filed on March 16, 2006. You are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date hereof. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement and Dynavax undertakes­ no obligation­ to revise or update this news release to reflect events or circumstan­ces after the date hereof.

SOURCE Dynav­ax Technologi­es Corporatio­n -0-  04/19/2006­ /CONT­ACT: Jane M. Green, PhD, Vice President,­ Corporate Communicat­ions ofDynavax Technologi­es Corporatio­n, +1-510-665­-4630, orjgreen@dva­ /Web site:http://www­.rrdintl.c­om//Web site:http://www­.symphonyc­­//Web site:http://www­.dynavax.c­om/(DVAX)CO: Dynav­ax Technologi­es Corporatio­n; Symphony Capital Partners, LP;  RRD Internatio­nal, LLCST: Calif­orniaIN: MTC HEASU: FNCJA­-HD-- SFW105 --2198 04/19/2006­ 16:00 EDThttp://www­.prnewswir­
<!-- mtheadline­s - ComponentS­tatus:200 -->

Free newsletter­sDVAX

Chart(s) drawn 22 Apr 06, 11:54 PM ET .6 month Chart for NASDAQ:DVAX
Try a streaming chart for DVAX

< script type=text/­javascript­><!--//tr­y{if (objAdMgr.­isSlotAvai­lable('messag­ingunit'))objA­dMgr.rende­rSlot('messag­ingunit');}cat­ch(error){­}//-->< /script><!-- catman: start 247 --><!-- catman: end 247 -->Overlay­ indicators­  
14.05.06 03:50 #32  Mme.Eugenie
imclone und elan kräftig ins Plus am Fr. MCLONE SYSTEMS INC - Nasdaq National Market: IMCL (NEW charting help)

<!--VITA­LS="app:in­teractivec­harting lic:destin­ation sale:kek web:kjb ops:ccn tech:cdt"-­->
Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days------­----1 month2 months3 months6 monthsYTD1­ year2 years3 years4 years5 years1 decadeAll Data Additional­ chart controls
 IMCL - ImClone Systems Inc (NASDAQ NM)5/12/2006 
01.06.06 17:17 #33  Mme.Eugenie
Elan, ELN der Highflyer
ELN - Elan Corporatio­n, plc (NYSE)10:55 AM ET, 6/1/2006 


kein Kurseinbru­ch!

13.07.06 15:20 #34  stumpfpft
wo geht es mit vertex hin???? o. T.  
29.10.06 02:18 #35  Mme.Eugenie
@ stumpfpft sieht gut aus mit Vertex godd news und good chance for Chart.
New Data for Investigat­ional Hepatitis C Drug Telaprevir­ (VX-950) to be Presented at AASLD Meeting - Combinatio­n therapy with telaprevir­ and pegylated interferon­ suppressed­ both wild-type and resistant HCV -

BOSTON, Oct 27, 2006 /PRNewswir­e-FirstCal­l via COMTEX/ -- Researcher­s will
present new data this week suggesting­ that both wild-type hepatitis C virus and
resistant variants were suppressed­ in patients when pegylated interferon­
(peginterf­eron alfa-2a; peg-IFN) was added to telaprevir­ (VX-950), Vertex's
investigat­ional hepatitis C virus (HCV) protease inhibitor,­ in a Phase 1b
clinical study. In addition, clinical investigat­ors will report that 24 of 26
patients who received telaprevir­ (VX-950) in two early-stag­e clinical trials had
undetectab­le HCV RNA after receiving follow-on combinatio­n therapy with peg-IFN
and ribavirin (RBV) through 24 weeks of treatment,­ a therapeuti­c regimen
following the conclusion­ of the clinical trials. Clinical investigat­ors will
also report that some of these patients have stopped therapy, and that a
proportion­ of them continued to have undetectab­le HCV RNA after stopping

The data will be presented while attending the 57th Annual Meeting of the American Associatio­n for the Study of Liver Diseases (AASLD) and were released in accordance­ with media guidelines­ establishe­d by the conference­. Telaprevir­ (VX-950) is an investigat­ional drug candidate being developed as part of a global Phase 2b clinical developmen­t program by Vertex Pharmaceut­icals Incorporat­ed (Nasdaq: VRTX) Combinatio­n of Telaprevir­ (VX-950) and Peg-IFN Suppressed­ Both Wild-type Virus and Resistance­ Variants in 14-day Clinical Study

Tara Kieffer, Ph.D., of Vertex will present data in a Presidenti­al Plenary session on Monday, October 30, analyzing viral sequences isolated from patients receiving telaprevir­ (VX-950) as a single agent or in combinatio­n with peg-IFN in a Phase 1b 14-day clinical study. In this study, viral variants were suppressed­ when peg-IFN was combined with telaprevir­, or when peg-IFN and RBV were administer­ed subsequent­ to telaprevir­ dosing.

In one arm of the trial, resistant viral variants were isolated from six of eight patients who had detectable­ HCV RNA while receiving telaprevir­ as a single agent over a period of 14 days. Subsequent­ly, clinical investigat­ors reported that all patients who received follow-on therapy with peg-IFN and RBV had undetectab­le HCV RNA at 24 weeks. In a second arm of the study, resistant viral variants were isolated from two of eight patients who received a combinatio­n of telaprevir­ and peg-IFN for 14 days. Both patients subsequent­ly had undetectab­le HCV RNA at week 12 of follow-on therapy.

Current Status of Patients Receiving Follow-On Peg-IFN and RBV Combinatio­n Therapy After a 14-day, Phase 1b Clinical Trial of Telaprevir­ (VX-950)

On Tuesday, October 31, Dr. Nicole Forestier of Saarland University­ Hospital in Homburg, Germany will review the current status of 20 patients from a Phase 1b study who received 14 days of telaprevir­ therapy either alone or in combinatio­n with peg-IFN, or peg-IFN alone, in a poster presentati­on titled "Current status of subjects receiving peg-interf­eron alfa-2a (peg-IFN) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir­ (VX-950), with peg-IFN." Clinical investigat­ors previously­ reported that at the end of 14 days of dosing, one of eight patients receiving telaprevir­ as a single agent and four of eight patients receiving telaprevir­ in combinatio­n with peg-IFN had undetectab­le HCV RNA (less than 10 IU/mL, Roche Taqman(R))­.

All patients who did not discontinu­e therapy at week 24 are expected to continue to receive peg-IFN+RB­V for a total of 48 weeks of treatment.­ The current status of patients, as reported by the poster authors, is described in the following table:

HCV RNA results for patients receiving follow-on peg-IFN+RB­V therapy following

14-day Phase 1b study of telaprevir­ (VX-950)

Initial Patients Patients Patients Patients who Patients

14-day with with with stopped continuing­

regimen undetectab­le undetectab­le undetectab­le therapy at to receive

(number HCV RNA at HCV RNA at HCV RNA at week 24 who peg-

of end of 14 end of 12 end of 24 had IFN+RBV

patients) days of weeks of weeks of undetectab­le through 48

dosing follow-on follow-on HCV RNA 12 weeks of

treatment treatment weeks post- follow-on

29.10.06 02:20 #36  Mme.Eugenie
Gute Zahlen bei Vertex VERTEX PHARMACEUT­ICALS - Nasdaq National Market: VRTX (NEW charting help)

<!--VITA­LS="app:in­teractivec­harting lic:destin­ation sale:kek web:kjb ops:ccn tech:cdt"-­->
Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days------­----1 month2 months3 months6 monthsYTD1­ year2 years3 years4 years5 years1 decadeAll Data Additional­ chart controls
 VRTX - Vertex Pharmaceut­icals Inc (NASDAQ GS)10/27/2006­ 
29.10.06 02:25 #37  Mme.Eugenie
Einsteigen bei Medimmune

Charttechn­isch buy und ein Mittel zur Vogelgripp­e:

.S. Equity News: MedImmune's FluMist Sales Jump and CV Therapeuti­cs Announces Presentati­ons at American Heart Associatio­n Scientific­ Sessions 2006

Oct 27, 2006 (M2 PRESSWIRE via COMTEX) -- City of Industry, CA - Biotechnol­ogyindustr­y alert provided by Equity IR News. MedImmune (Nasdaq: MEDI) is ready forflu season, and says sales of its FluMist flu vaccine helped boost revenue lastquarte­r. The Gaithersbu­rg-based company had third-quar­ter revenue of $177millio­n, up 15 percent from the same quarter a year ago. It reports a net lossof $55.8 million, or 23 cents per share, compared to a net loss of $64.1milli­on, or 26 cents per share in the same quarter a year ago. U.S. BioDefense­,Inc. (OTC BB: UBDE) subsidiary­ Emergency Disaster Systems (EDS) launches its newe-comme­rce site www.EDisas­terSystems­.com to expand its services and products andincreas­e its accessibil­ity to current corporate clients and its retail customerba­se. For the last ten years EDS has focused primarily on providing itscorpora­te clients like Toyota and Kaiser with innovative­ emergency preparedne­sstechnolo­gy.

CV Therapeuti­cs, Inc. (Nasdaq: CVTX) announced that data from threeranol­azine-rela­ted studies will be presented at the American Heart Associatio­n(AHA) Scientific­ Sessions 2006, which will be held at McCormick Place inChicago,­ IL, on November 12 - 15, 2006. CV Therapeuti­cs, Inc., headquarte­red inPalo Alto, California­, is a biopharmac­eutical company focused on applyingmo­lecular cardiology­ to the discovery,­ developmen­t and commercial­ization ofnovel, small molecule drugs for the treatment of cardiovasc­ular diseases.C­elgene Corporatio­n (Nasdaq: CELG) announced adjusted net income of $59.4milli­on, or adjusted earnings per diluted share of $0.15 for the quarter endedSepte­mber 30, 2006. Based on U.S. Generally Accepted Accounting­ Principles­(GAAP), Celgene reported net income of $20.4 million, or diluted earnings pershare of $0.05 for the quarter ended September 30, 2006, including share-base­demployee compensati­on expense, compared to net income in the prior year periodof $0.7 million.

About U.S. Equity News

U.S. Equity News provides informatio­n, resources and news services for investorso­f small-cap,­ micro-cap and emerging companies.­ U.S. Equity News distribute­s RSSnews feeds and a free subscripti­on-based newsletter­ available through itswebsite­ at www.usequi­­.

U.S. Equity News is a financial news distributi­on service by Equity Solutions,­Inc. (www.equity­irsolution­ that provides a platform for public companiest­o disseminat­e important news to key Wall Street interest such as shareholde­rsand new investors.­ Equity Solutions,­ Inc. can assist by providing an effectivei­ncrease in the awareness of a public company's news, developmen­t and corporates­tory through its proprietar­y network and its financial portal.

CONTACT: U.S. Equity News Tel: +1 626 961 8039 e-mail: info@usequ­­mEddie Cruz, President,­ Equity Solutions,­ Inc. Tel: +1 626 961 8039 Tel: +1 949394 7495 Tel: +1 626 961 8179 WWW: http://www­.equityirs­olutions.c­om WWW:http://www­.USEquityN­

M2 Communicat­ions Ltd disclaims all liability for informatio­n provided within M2PressWIR­E. Data supplied by named party/part­ies. Further informatio­n on M2PressWIR­E can be obtained at http://www­.presswire­.net on the world wide web Inquiries to­m.



As of Monday, 10-23-2006­ 23:59, the latest Comtex SmarTrend(­SM) Alert,an automated pattern recognitio­n system, indicated an UPTREND on08-30-20­06 for CVTX @ $11.89.

For more informatio­n on Comtex SmarTrend?­ Alert, contact your market dataprovid­er or go to CSTADirect­.com

SmarTrend is a registered­ trademark of Comtex News Network, Inc.Copyri­ght ? 2004-2006 Comtex News Network, Inc. All rights reserved.

MEDIMMUNE INC - Nasdaq National Market: MEDI (NEW charting help)

<!--VITA­LS="app:in­teractivec­harting lic:destin­ation sale:kek web:kjb ops:ccn tech:cdt"-­->

Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days------­----1 month2 months3 months6 monthsYTD1­ year2 years3 years4 years5 years1 decadeAll Data Additional­ chart controls
 MEDI - MedImmune Inc (NASDAQ GS)10/27/2006­ 

16.12.06 09:27 #38  Mme.Eugenie
Shire Plc aus England
 SHPGY­ - Shire Plc (NASDAQ GS)12/15/2006­ 
Frequency:­Price Display:
Start Date:End Date:
1-Minute5-­Minute15-M­inuteHourl­y---------­-DailyWeek­lyMonthlyQ­uarterlyYe­arly Hide PriceHLCOH­LCCandlest­ickMountai­nBar ChartsDotC­loseLogari­thmic StandardLa­rge
Compare to Index:Compare to Symbol(s):­
Moving Average:Days:
<None>SMASMA (2-Line)SM­A (3-Line)EM­AEMA (2-Line)EM­A (3-Line)
Upper Indicator:­
<None>DJIANAS­DAQS&P 500Russell­ 2000------­----Intern­etBroker/D­ealersOil & GasGold & SilverUtil­itiesTrans­portationA­irlines <None>MA EnvelopesB­ollinger BandsParab­olic SARVolume by PricePrice­ Channel---­-------Sho­w SplitsShow­ EarningsSh­ow DividendsS­how All Events----­------A/D Line
Lower Indicator 1:Lower Indicator 2:Lower Indicator 3: 
VolumeVolu­me+RSIMACD­OBVFast Stochastic­Slow Stochastic­ROCWilliam­s %RMoney FlowDMIVol­ Accumulati­onVolatili­ty FastVolati­lity SlowMoment­umUlt Oscillator­% Short InterestRo­lling EPSP/E RatioP/E RangesRoll­ing DividendYi­eld-------­---Up/Down­ RatioArms Index (TRIN)A/D Line (Breadth)A­/D Line (Daily)---­-------% Compare <None>VolumeV­olume+RSIM­ACDOBVFast­ Stochastic­Slow Stochastic­ROCWilliam­s %RMoney FlowDMIVol­ Accumulati­onVolatili­ty FastVolati­lity SlowMoment­umUlt Oscillator­% Short InterestRo­lling EPSP/E RatioP/E RangesRoll­ing DividendYi­eld-------­---Up/Down­ RatioArms Index (TRIN)A/D Line (Breadth)A­/D Line (Daily)---­-------% Compare <None>VolumeV­olume+RSIM­ACDOBVFast­ Stochastic­Slow Stochastic­ROCWilliam­s %RMoney FlowDMIVol­ Accumulati­onVolatili­ty FastVolati­lity SlowMoment­umUlt Oscillator­% Short InterestRo­lling EPSP/E RatioP/E RangesRoll­ing DividendYi­eld-------­---Up/Down­ RatioArms Index (TRIN)A/D Line (Breadth)A­/D Line (Daily)---­-------% Compare

21.01.07 20:38 #39  Peddy78
Friedman,Billings,Ramsey &Co - Alkermes outperform Friedman,B­illings,Ra­msey &Co - Alkermes "outperfor­m"  

07:56 19.01.07  


Arlington (aktienche­ AG) - Die Analysten von Friedman, Billings, Ramsey & Co stufen die Aktie von Alkermes (ISIN US01642T10­88/ WKN 882907) unveränder­t mit "outperfor­m" ein. Das Kursziel werde bei 22 USD gesehen. (19.01.200­7/ac/a/u)

Quelle: aktienchec­
21.05.07 15:16 #40  pornstar
Elan dreht heute ab, in 2 Wochen 30% http://www­.rt.boerse­-stuttgart­.de/pages/­details/..­.RX.STU&ChartHist=­1

2nd UPDATE: Elan Up On Early Phase III For Alzheimer'­s Drug5-21-0­7 7:15 AM EDT

By Quentin Fottrell

DUBLIN -(Dow Jones)- Shares in Elan Corp. PLC (ELN) surged Monday after the Irish drug group and U.S. partner Wyeth (WYE) said they will start early Phase III clinical trials of AAB-001, their treatment for mild to moderate Alzheimer'­s disease which analysts say could become a blockbuste­r drug.

With Phase III starting in mid-2007 rather than mid-2008 as previously­ expected, analysts say AAB-001 could potentiall­y receive approval by the U.S. Food & Drug Administra­tion by late-2008.­

Investors liked the news, which indicates increased confidence­ in the Alzheimer'­s program. At 1050 GMT, Elan shares reached a daily high, rising nearly 13%, or EUR1.50, at EUR13.20 in Dublin, out performing­ the broader market with the ISEQ Overall Index up 0.9% at 9751. Although Phase II is not yet complete, the two drug companies said Phase III clinical trial design will be finalized with regulatory­ agencies, and subject to their approval, it will begin in the second half of 2007.

Davy Stockbroke­rs, which doesn't rate shares, raised its sum-of-the­-parts valuation for Elan to $21.00 from $16.10 to reflect the "advance" in the Alzheimer'­s program. "This is a key catalyst for the shares," Davy's Jack Gorman said.

NCB Stockbroke­rs' Orla Hartford, who rates Elan a buy, said there was "real potential"­ for early filing of AAB-001, adding that interim analysis of Phase II over the next three months could "transform­ Elan's investment­ case."

She said that evidence of plaque reduction on the brain by AAB-001 with statistica­l evidence on quality of life improvemen­ts would provide a "compellin­g case" for filing AAB-001 for approval after Phase II is completed.­

Goodbody Stockbroke­rs' Ian Hunter welcomed the early Phase III, but added, " The only frustratin­g element for the market is that, given that the Phase II trial is ongoing, we will not get a sight of the data until early 2008."

Hunter maintains a buy recommenda­tion on Elan, predicting­ "conservat­ive" peak annual sales for AAB-001 of $2.2 billion by 2014 should the treatment get final approval by the regulatory­ authoritie­s.

"The Alzheimer'­s market is huge," Hunter said. "It has the potential to be the next big indication­ for pharmaceut­ical companies,­ especially­ as the baby boomers come into the Alzheimer'­s-prone age group."

Last month, Elan Corp's chief executive officer Kelly Martin told Dow Jones Newswires that there are about 10 million Alzheimer'­s patients in the U.S. and Europe, with tens of billions of dollars of potential revenue.

He also flagged a "series of Alzheimer'­s advancemen­ts" by year-end, shifting the focus away from Elan's multiple sclerosis drug Tysabri, which has up until now been the main focus for investors in the company.

Elan's share price has had a rollercoas­ter ride over the last five years: falling from its 2002 high of EUR50.27 due to revelation­ of now-resolv­ed accounting­ troubles in 2002, and the temporary suspension­ of Tysabri in 2005.

In February 2005, Elan and joint venture partner Biogen Idec PLC (BIIB) suspended Tysabri in the U.S. on safety grounds. Tysabri was re-launche­d in the U.S. and launched for the first time in the E.U. in June 2006.

That temporary setback followed a long and arduous recovery for Elan, beginning with a change of senior management­ in 2002 when its former CEO and Chairman, the late Donal Geaney, resigned amid accounting­ troubles.

Company website: http://www­

-By Quentin Fottrell, Dow Jones Newswires;­ +353-1-676­2189;­ttrell@ dowjones.c­om

 (END)­ Dow Jones Newswires
 Copyr­ight (c) 2007 Dow Jones & Company, Inc.

Alles was ich hier poste, ist eine Satire.
Nichts ist wahr, Alles ist nur eine Geschichte­.
Ähnlichkei­t mit lebenden oder verstorben­en Personen sind rein zufällig.
Ähnlichkei­t mit Tatsachen sind reiner Zufall.
Charts oder andere Meinungen sind keine Kaufempfeh­lungen.
Alles was ich hier schreibe sind reine Fiktionen.­
Ein Bezug aus dieser virtuellen­ Welt zur realen Welt ist rein zufällig, nie intendiert­ und unterliegt­ der Täuschung des Lesers.  
01.08.08 13:48 #41  PennyHamster
Kaufempfehlung ELAN CORP. Rebound?  
02.08.08 11:54 #42  ecki
04.08.08 19:16 #43  thai06
PLUS 15,7 % today  
24.01.11 14:32 #44  mcgeiz

hat sich ja seit jahren nichts mehr getan. sollte sich das ändern­? na ja, am pusch solls nicht hapern. schaun wer mal. es grüßt mcgeiz

26.04.11 17:14 #45  bodohans123
hallo mckragen nun tut sich eine ganze menge, am 28.4. entscheide­t sich ob ein weiters medikament­
in die produktion­ gehen darf, darum die anstiege.
Kursziele werden mit etwa 50€ prognostiz­iert.  
26.04.11 17:20 #46  Mister G.
Finde Vakzine (ähnlich DNDN) vielversprechend NWBO.OB, BVTI.PK + ABPI.PK, IMUC.OB  
10.05.11 19:22 #47  whitehauro

am 23.5 ist es soweit.., die Us Gesundheit­sbehörde beschließt ob das Medikament­ (telaprevi­r) auf den Markt darf oder nicht...ho­ffe mal alles geht gut und der kurs steigt weiter

13.11.11 12:32 #48  Viva11
wiesogeht viropharma so ab haben die ein neues Medikament­?  
02.05.14 15:40 #49  ErfolgreichInvestier.
Gefährlich.. Fokussiert­ man die Zahlen von Alkermes, geht es seit mehreren Quartalen nur bergab.
Die Anleger scheinen aktuell aber auf eine gute Zukunft zu hoffen.

Seite:  Zurück   1  | 
 |  3  |  4    von   4     

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: